PURPOSE: To investigate the effects of topical @entity37086 0.1  % on @entity697 (CSC). METHODS: The medical records of 52 cases (52 @entity1 ) of CSC were retrospectively reviewed. Twenty-six @entity1 were treated with topical @entity37086 0.1  % (treatment group) and 26 @entity1 did not receive treatment (control group). Baseline and follow-up values for visual acuity, @entity3193 ( @entity3193 ), subretinal fluid (SRF) maximum height, and @entity1020 ( @entity1020 ) were examined and compared between groups. RESULTS: In the treatment group, mean @entity3193 decreased from 365.5        52.9   m at baseline to 288.9        36.1   m at 6  months after initiation of treatment (p   =   0.005). Both SRF maximum height and @entity1020 were also decreased from baseline at 1  month (SRF maximum height, baseline: 221.5        108.4, 1  month: 97.7        54.3   m, p   =   0.002; @entity1020 , baseline: 403.9        114.6, 1  month: 270.1        37.9   m, p   =   0.003). In the control group, @entity3193 decreased throughout the follow-up period, but the change was not significant. Subretinal fluid maximum height and @entity1020 were significantly decreased after 3  months in the control group (SRF, baseline: 265.4        112.4   m, 6  months: 64.8        116.9   m, p   =   0.005; @entity1020 , baseline: 459.1        104.9   m, 6  months: 304.6        92.8   m, p   <   0.001). Visual acuity was improved from baseline in both groups after 6  months, but the improvement was only significant in the treatment group (p   =   0.002). The rate of disease recurrence was lower in the treatment group (23  %) than in the control group (38  %), but this difference between groups was not statistically significant (p   =   0.229, chi-square test). CONCLUSIONS: Topical @entity37086 0.1  % was effective in treating acute CSC, as demonstrated by an increase in visual acuity and a decrease in SRF, @entity3193 , and @entity1020 after treatment. These results suggest that topical @entity37086 0.1  % may be useful in treating @entity1 with acute CSC.

Effect of a topical nonsteroidal anti-inflammatory agent (0.1  % XXXX ) on @entity697 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity697 :: ('MESH:D000208', 'Disease') :: ['acute central serous chorioretinopathy'] @entity3193 :: ('MESH:D015862', 'Disease') :: ['subfoveal choroidal thickness', 'SCT'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness'] @entity37086 :: ('MESH:C043940', 'Chemical') :: ['pranoprofen']
@entity37086 :: (MESH:C043940,Chemical) :: ['pranoprofen']
